Phospholipase A2 and the Pathogenesis of Multisystem Organ Failure in Experimental and Clinical Endotoxin Shock

  • Peter Vadas
  • Jeffrey Edelson
  • Waldemar Pruzanski
Chapter
Part of the NATO ASI Series book series (NSSA, volume 266)

Abstract

Synthesis and activation of phospholipases A2 have been recognized to be an integral part of the host’s response to inflammatory and infectious agents. Several functionally and structurally distinct phospholipases A2 are present in humans. Their respective roles have not been fully elucidated. A growing body of evidence has implicated the secretory nonpancreatic phospholipase A2 (sPLA2) in the pathogenesis of the major manifestations of endotoxin shock. Herein, we will review the evidence implicating sPLA2 in the pathogenesis of septic shock in the context of the biochemical characterization, sources of synthesis in systemic inflammatory reactions such as endotoxin shock, endogenous regulation of synthesis and signal transduction pathways, endogenous modulation of activity of secreted PLA2 and experimental data which further substantiates the involvement of sPLA2 in the initiation and propagation of local and systemic inflammatory reactions.

Keywords

Septic Shock Acute Lung Injury Acute Phase Protein Adult Respiratory Distress Syndrome Endotoxin Shock 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Tohkin, M, Kishino, J., Ishizaki, et al. Pancreatic-type phospholipase A2 stimulates prostaglandin synthesis in mouse osteoblastic cells (MC3T3–E1) via a specific binding site. J Biol Chem, 268: 1993; 2865–2871PubMedGoogle Scholar
  2. 2.
    Leslie, C.C., and Channon, J.Y. Anionic phospholipids stimulate an arachidonoyl-hydrolyzing phospholipase A2 from macrophages and reduce the calcium requirement for activity. Biochim Biophys Acta, 1045: 1990; 261–270.PubMedCrossRefGoogle Scholar
  3. 3.
    Vadas, P, and Hay, J.B. Involvement of circulating phospholipase A2 in the pathogenesis of the hemodynamic changes in endotoxin shock. Can J Physiol Pharmacol, 61: 1983; 561–566.PubMedCrossRefGoogle Scholar
  4. 4.
    Vadas, P, and Pruzanski, W. Induction of group II phospholipase A2 expression and pathogenesis of the sepsis syndrome, Circ Shock, 39: 1993; 160–167.PubMedGoogle Scholar
  5. 5.
    Nakano, T., and Arita, H. Enhanced expression of group Il phospholipase A2 gene in the tissues of endotoxin shock rats and its suppression by glucocorticoid, FEBS Lett, 273: 1990; 23–26PubMedCrossRefGoogle Scholar
  6. 6.
    Vadas, P., Browning, J., Edelson, J., et al. Extracellular phospholipase A2 expression and inflammation:the relationship with associated disease states, J Lipid Mediators, 8: 1993; 1–30.Google Scholar
  7. 7.
    Pfeilschifter, J., Leighton, J, Pignat, W, et al. Cyclic AMP mimics, but does not mediate, interleukin-1 and tumour-necrosis-factor-stimulated phospholipase A2 secretion from rat mesangial cells. Biochem J, 273: 1991; 199–204PubMedGoogle Scholar
  8. 8.
    Nakano, T., Ohara, O, Teraoka, H., et al. Group II phospholipase A2 mRNA synthesis is stimulated by two distinct mechanisms in rat vascular smooth muscle cells, FEBS Lett, 261: 1990; 171–174PubMedCrossRefGoogle Scholar
  9. 9.
    Schultz, D.R., and Arnold, P.I. Properties of four acute phase proteins: C-reactive protein, serum amyloid A protein, a1-acid glycoprotein, and fibrinogen, Seminars in Arthritis and Rheumatism. 20: 1990; 129–147Google Scholar
  10. 10.
    Vadas, P., Schouten, B.D., Stefanski, E., et al. Association of hyperphospholipasemia A2 with multiple system organ dysfunction due to salicylate intoxication. Crit Care Med, 21: 1990; 1087–1091.CrossRefGoogle Scholar
  11. 11.
    Hallman, M., Spragg, R., Harrell, J.H., et al. Evidence of lung surfactant abnormality in respiratory failure. Study of bronchoalveolar lavage phospholipids, surface activity, phospholipase activity and plasma myoinositol, J Clin Invest. 70: 1982; 673–683PubMedCrossRefGoogle Scholar
  12. 12.
    Gregory, T.J., Longmore, W.J., Moxley, M.A. et al. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome, J Clin Invest. 88: 1991; 1976 1981Google Scholar
  13. 13.
    Von Wichert, P., Tennesfeld, M., and Meyer, W. Influence of septic shock upon phosphatidylcholine remodelling mechanism in rat lung, Biochim Biophys Acta 664: 1981; 487–497.CrossRefGoogle Scholar
  14. 14.
    Edelson, J.D., Vadas, P., Mullen, B, et al. Phospholipase A2–induced acute lung injury in rats, Am Rev Respir Dis 143: 1991; 1102–1109.PubMedCrossRefGoogle Scholar
  15. 15.
    Mullen, J.B.M., Pittman, J.A., Feinmesser, M.E., and Edelson, J.D. Phospholipase A2 -induced lung injury; morphometric analysis. Am Rev Respir Dis 145: 1992; A606Google Scholar
  16. 16.
    Holm, B.A., Keicher, L., Liu, M.Y. et al. Inhibition of pulmonary surfactant function by phospholipases. J Appl Physiol, 71: 1991; 317–321.PubMedGoogle Scholar
  17. 17.
    Cockshutt, A.M., and Possmayer, F. Lysophosphatidylcholine sensitizes lipid extracts of pulmonary surfactant to inhibition by serum proteins. Biochim Biophys Acta, 1086: 1991; 63–71.PubMedCrossRefGoogle Scholar
  18. 18.
    Edelson, J.D., Vadas, P., Pruzanski, W., et al. Phospholipase A2 is cytotoxic to alveolar type II cells, Am Rev Respir Dis 145: 1992; A360Google Scholar
  19. 19.
    Pruzanski, W., Wilmore, D.W., Suffredini, A. et al. Hyperphospholipasemia A2 in human volunteers challenged with intravenous endotoxin. Inflammation, 16: 1992; 561–570.PubMedCrossRefGoogle Scholar
  20. 20.
    Pruzanski, W., Mackensen, A, Engelhardt, R, et al. Induction of circulating phospholipase A2 activity by intravenous infusion of endotoxin in patients with neoplasia. J Immunotherapy, 12: 1992; 242–246.CrossRefGoogle Scholar
  21. 21.
    Pruzanski, W., Sherman, M.L., Kufe, D.W., et al. Induction of circulating phospholipase A2 by intravenous administration of recombinant human tumour necrosis factor. Mediators Inflam, 1: 1992; 235–240.CrossRefGoogle Scholar
  22. 22.
    Vadas, P. Elevated plasma phospholipase A2 levels: Correlation with the hemodynamic and pulmonary changes in gram-negative septic shock. J Lab Clin Med, 104: 1984; 873–881.Google Scholar
  23. 23.
    Vadas, P., Pruzanski, P., Stefanski, E. et al. Pathogenesis of hypotension in septic shock: Correlation of circulating phospholipase A2 levels with circulatory collapse. Crit Care Med, 16: 1988; 1–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Scott, K.F., Smith, G.M., Green, J.A., et al. Neutralising monoclonal antibody to human secretory phospholipase A2 is anti-hypotensive in a baboon E. coli induced septic shock model, in “Prostaglandins and Related Compounds”, 1992; A151.Google Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • Peter Vadas
    • 1
  • Jeffrey Edelson
    • 1
  • Waldemar Pruzanski
    • 1
  1. 1.Divisions of Immunology and Respirology Department of MedicineUniversity of TorontoTorontoCanada

Personalised recommendations